

Assoc. Prof. YAĞMUR AKDAĞ ÇAYLI

Personal Information

Email: yagmur.akdag@hacettepe.edu.tr

Web: <https://avesis.hacettepe.edu.tr/yagmur.akdag>

International Researcher IDs

ORCID: 0000-0003-4139-9815

ScopusID: 57209399306

Yoksis Researcher ID: 166650

Education Information

Doctorate, Hacettepe University, Eczacılık Fakültesi, Turkey 2011 - 2017

Undergraduate, Hacettepe University, Eczacılık Fakültesi, Turkey 2005 - 2010

Dissertations

Doctorate, Antibiyotik İçeren Kuru Toz İnhaler Formülasyonu Tasarımı ve Permeabilite Çalışmaları, Hacettepe Üniversitesi, Eczacılık Fakültesi, Eczacılık Teknolojisi Bölümü, 2017

Research Areas

Health Sciences, Pharmacology and Therapeutics, Pharmaceutics Technology, Pharmaceutical Technology, Biopharmaceutical and Pharmacokinetics

Academic Titles / Tasks

Associate Professor, Hacettepe University, Eczacılık Fakültesi, Eczacılık Teknolojisi Bölümü, 2023 - Continues

Assistant Professor, Hacettepe University, Eczacılık Fakültesi, Eczacılık Teknolojisi Bölümü, 2020 - 2023

Research Assistant, Hacettepe University, Eczacılık Fakültesi, Eczacılık Teknolojisi Bölümü, 2011 - 2020

Published journal articles indexed by SCI, SSCI, and AHCI

I. Electrospun nanofiber drug delivery systems and recent applications: An overview

Muratoglu S., Inal M., AKDAĞ ÇAYLI Y., GÜLSÜN İNAL T., ŞAHİN S.

Journal of Drug Delivery Science and Technology, vol.92, 2024 (SCI-Expanded)

II. Antibody Conjugated Nano-Enabled Drug Delivery Systems Against Brain Tumors

Topçu B. T., Bozdağ Pehlivan S., AKDAĞ ÇAYLI Y., Mut M., ÖNER L.

Journal of Pharmaceutical Sciences, 2024 (SCI-Expanded)

III. Celecoxib Nanoformulations with Enhanced Solubility, Dissolution Rate, and Oral Bioavailability:

Experimental Approaches over In Vitro/In Vivo Evaluation

Arslan A., YET B., NEMUTLU E., AKDAĞ ÇAYLI Y., EROĞLU H., ÖNER L.

Pharmaceutics, vol.15, no.2, 2023 (SCI-Expanded)

- IV. **Nanoparticle-Containing Lyophilized Dry Powder Inhaler Formulations Optimized Using Central Composite Design with Improved Aerodynamic Parameters, and Redispersibility.**
Akdag Y.
Pharmaceutical development and technology, vol.28, no.1, pp.124-137, 2023 (SCI-Expanded)
- V. **Design of Besifloxacin HCl-Loaded Nanostructured Lipid Carriers: In Vitro and Ex Vivo Evaluation**
POLAT H. K., Kurt N., AYTEKİN E., AKDAĞ ÇAYLI Y., Pehlivan S., ÇALIŞ S.
JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS, vol.38, no.6, pp.412-423, 2022 (SCI-Expanded)
- VI. **The development and characterization of electrospun gelatin nanofibers containing indomethacin and curcumin for accelerated wound healing**
Gulsun T., Inal M., Akdag Y., İZAT N., ÖNER L., ŞAHİN S.
Journal of Drug Delivery Science and Technology, vol.67, 2022 (SCI-Expanded)
- VII. **Development and characterization of metformin hydrochloride- and glyburide-containing orally disintegrating tablets**
GÜLSÜN İNAL T., AKDAĞ ÇAYLI Y., İZAT N., ÇETİN M., ÖNER L., ŞAHİN S.
PHARMACEUTICAL DEVELOPMENT AND TECHNOLOGY, vol.25, no.8, pp.999-1009, 2020 (SCI-Expanded)
- VIII. **Development of an Anti-Inflammatory Drug-Incorporated Biomimetic Scaffold for Corneal Tissue Engineering**
Celebier S. K., Pehlivan S., DEMİRBILEK M., Akinci M., VURAL İ., AKDAĞ ÇAYLI Y., Yuruker S., Unlu N.
Journal of Ocular Pharmacology and Therapeutics, vol.36, no.6, pp.433-446, 2020 (SCI-Expanded)
- IX. **Characterization and comparison of deferasirox fast disintegrating tablets prepared by direct compression and lyophilization methods**
AKDAĞ ÇAYLI Y., GÜLSÜN İNAL T., İZAT N., ÇETİN M., ÖNER L., ŞAHİN S.
JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY, vol.57, 2020 (SCI-Expanded)
- X. **Comparison of Dissolution Profiles and Apparent Permeabilities of Commercially Available Metformin Hydrochloride Tablets in Turkey**
AKDAĞ ÇAYLI Y., GÜLSÜN İNAL T., İZAT N., ÖNER L., ŞAHİN S.
DISSOLUTION TECHNOLOGIES, vol.27, no.1, 2020 (SCI-Expanded)
- XI. **Cyber-physical-based PAT (CPbPAT) framework for Pharma 4.0**
Barenji R. V., Akdag Y., YET B., ÖNER L.
INTERNATIONAL JOURNAL OF PHARMACEUTICS, vol.567, 2019 (SCI-Expanded)
- XII. **Effect of particle size and surfactant on the solubility, permeability and dissolution characteristics of deferasirox**
Gulsun T., Akdag Y., İZAT N., ÖNER L., ŞAHİN S.
Journal of Research in Pharmacy, vol.23, no.5, pp.851-859, 2019 (SSCI)
- XIII. **Determination of N-acetylcysteine in the presence of ciprofloxacin or levofloxacin in microparticulate dry powder inhalers**
Akdag Y., ŞAHİN S., NEMUTLU E., ÖNER L.
TURKISH JOURNAL OF CHEMISTRY, vol.43, no.3, pp.846-856, 2019 (SCI-Expanded)
- XIV. **Development and evaluation of terbutaline sulfate orally disintegrating tablets by direct compression and freeze drying methods**
Gulsun T., Cayli Y., İZAT N., ÇETİN M., ÖNER L., ŞAHİN S.
Journal of Drug Delivery Science and Technology, vol.46, pp.251-258, 2018 (SCI-Expanded)
- XV. **Dry powders for the inhalation of ciprofloxacin or levofloxacin combined with a mucolytic agent for cystic fibrosis patients.**
Akdag C., SAHIN S., BUTTINI F., BALDUCCI A., MONTANARI S., VURAL I., ONER L.
Drug development and industrial pharmacy, vol.43, pp.1378-1389, 2017 (SCI-Expanded)
- XVI. **Preparation and in vitro/in vivo evaluation of rofecoxib containing bovine serum albumin microspheres**
Demirturk E., Gulsun T., Cayli Y., İZAT N., ŞAHİN S., ÖNER L.
Latin American Journal of Pharmacy, vol.36, no.6, pp.1096-1104, 2017 (SCI-Expanded)

Articles Published in Other Journals

- I. **PHARMA 4.0 APPROACH IN PHARMACEUTICAL INDUSTRY**
Bebek G., AKDAG Y., ÖNER L.
Ankara Üniversitesi Eczacılık Fakültesi Dergisi, vol.47, no.3, pp.1058-1070, 2023 (Scopus)
- II. **Effects of Surfactants on Albumin Nanoparticles**
Akdag Y., Geyik Z. M.
Journal of Research in Pharmacy, vol.26, no.5, pp.1177-1189, 2022 (Scopus)
- III. **Formulation and characterization of mometasone furoate and formoterol fumarate containing dry powder inhaler by spray drying and homogenization methods**
AKDAĞ ÇAYLI Y., GÜLSÜN İNAL T., İZAT N., ÖNER L., ŞAHİN S.
JOURNAL OF RESEARCH IN PHARMACY, vol.26, no.2, pp.383-396, 2022 (ESCI)
- IV. **Evaluation of preparation methods for orally disintegrating tablets**
AKDAĞ ÇAYLI Y., GÜLSÜN İNAL T., İZAT N., ÇETİN M., ÖNER L., ŞAHİN S.
Medicine Science, vol.9, no.1, pp.259-263, 2020 (Peer-Reviewed Journal)
- V. **Development of dry powder inhaler formulations for drug delivery systems**
Akdağ Çaylı Y.
Journal of Research in Pharmacy, vol.23, no.6, pp.1-15, 2019 (Peer-Reviewed Journal)
- VI. **Development of dry powder inhaler formulations for drug delivery systems**
AKDAĞ ÇAYLI Y.
JOURNAL OF RESEARCH IN PHARMACY, vol.23, no.6, pp.973-987, 2019 (ESCI)
- VII. **Dry Powder Inhalers: Formulations and Aerodynamic Behaviours**
AKDAĞ ÇAYLI Y., ŞAHİN S., ÖNER L.
Hacettepe University Journal of the Faculty of Pharmacy, vol.38, no.1, pp.39-52, 2018 (Scopus)

Refereed Congress / Symposium Publications in Proceedings

- I. **Dry Powder Inhaler Formulations Containing Gefitinib Nanoparticles**
Geyik Z. M., Nacak B., Bilal M. N., Gülsün İnal T., Şahin S., Öner L., Akdağ Çaylı Y.
9th BBBB International Conference on Pharmaceutical Sciences 2022, Ljubljana, Slovenia, 15 - 17 September 2022, pp.178-179
- II. **Development of besifloxacin loaded nanostructured lipid carrier and characterization studies**
Kurt N., Polat H. K., Aytekin E., Akdag Çaylı Y., Pehlivan S., Çalış S.
20th International Pharmaceutical Technology Symposium - IPTS 2022, 21 - 23 February 2022, pp.1-2
- III. **Effects of spray drying and lyophilization methods on aerodynamic parameters in dry powder inhalers**
Akdağ Çaylı Y.
20th International Pharmaceutical Technology Symposium - IPTS 2022, Ankara, Turkey, 21 - 23 February 2022, pp.1-2
- IV. **Gefitinib-human serum albumin nanoparticles production by nanoparticle-albumin bound (NAB™) technology**
Geyik Z. M., Nacak B., Bilal M. N., Gülsün İnal T., Şahin S., Öner L., Akdağ Çaylı Y.
20th International Pharmaceutical Technology Symposium - IPTS 2022, 21 - 23 February 2022, pp.1-2
- V. **Effects of modifications in methyl cellulose nanoparticle production methods on particle size distribution**
Taş B., Akdag Çaylı Y., Pehlivan S., Aytekin E., Çopur T., Sağlam O., Öner L.
20th International Pharmaceutical Technology Symposium - IPTS 2022, 21 - 23 February 2022, pp.1-2
- VI. **Validation of an HPLC method for the determination of talazoparib from nanoparticle formulations**
Taş B., Akdag Çaylı Y., Aytekin E., Pehlivan S., Öner L., Kaplan O.
3rd International Gazi Pharma Symposium Series (GPSS-2021), 8 - 10 September 2021, pp.1-2

- VII. **Effects of Production Method Variations on Particle Size Distribution of Ethyl Cellulose Nanoparticles**
Taş B., Akdağ Çaylı Y., Aytekin E., Pehlivan S., Öner L.
13th International Symposium on Pharmaceutical Sciences (ISOPS), 22 - 25 June 2021, pp.1-2
- VIII. **HUMAN SERUM ALBUMIN NANOPARTICLES FOR TARGETED CANCER THERAPY**
AKDAĞ ÇAYLI Y., GEYİK Z. M.
13th International Symposium on Pharmaceutical Sciences (ISOPS), 22 - 25 June 2021
- IX. **Effects of Preparation Methods on Orally Disintegrating Tablets**
AKDAĞ ÇAYLI Y., GÜLSÜN İNAL T., İZAT N., ÇETİN M., ÖNER L., ŞAHİN S.
International Multidisciplinary Symposium on Drug Research Development (DRD 2019), 1 - 03 July 2019
- X. **Ağız yolu ile uygulanan etkin maddelerin çözünürlük ve permeabilite özelliklerini artırmak amacıyla formülasyon geliştirme sürecinde kullanılan yöntemler**
AKDAĞ ÇAYLI Y., GÜLSÜN İNAL T., İZAT N., ŞAHİN S., ÖNER L.
2. Ulusal Marmara Eczacılık Kongresi (UMEK-2), Turkey, 14 - 16 November 2018
- XI. **OPTIMIZATION OF NANOSYSTEMS CONTAINING ALBUMIN LINKED PACLITAXEL**
AKDAĞ ÇAYLI Y., MURAT Z., EROĞLU H., ÖNER L.
19th International Pharmaceutical Technology Symposium, 17 - 19 September 2018
- XII. **Investigation of deferasirox permeability from lyophilized orally disintegrating tablet**
GÜLSÜN İNAL T., İZAT N., AKDAĞ ÇAYLI Y., ÖNER L., ŞAHİN S.
2017 AAPS Annual Meeting and Exposition, 12 - 15 November 2017
- XIII. **Investigation of terbutaline sulfate permeability from orally disintegrating tablets**
İZAT N., AKDAĞ ÇAYLI Y., GÜLSÜN İNAL T., ÖNER L., ŞAHİN S.
2017 AAPS Annual Meeting and Exposition, 12 - 15 November 2017
- XIV. **Development and Characterization of Indomethacin and Curcumin Containing Nanofibers**
İNAL M., GÜLSÜN İNAL T., İZAT N., AKDAĞ ÇAYLI Y., ÖNER L., ŞAHİN S.
GPSS 2017, 11 - 13 October 2017
- XV. **Development and Evaluation of Lyophilized Orally Disintegrating Tablets Containing Metformin Hydrochloride and Glyburide**
AKDAĞ ÇAYLI Y., GÜLSÜN İNAL T., İZAT N., ÇETİN M., ÖNER L., ŞAHİN S.
77th FIP World Congress of Pharmacy and Pharmaceutical Sciences 2017, 10 - 14 September 2017
- XVI. **Antibiyotik İçeren Kuru Toz İnhaler Formülasyonları**
AKDAĞ ÇAYLI Y., ŞAHİN S., ÖNER L.
1. Anadolu Üniversitesi Eczacılık Fakültesi Sempozyumu (ANES), Turkey, 1 - 02 June 2017
- XVII. **Development and Validation of an HPLC method for Simultaneous Determination of Ciprofloxacin Levofloxacin and N acetylcysteine**
AKDAĞ ÇAYLI Y., ŞAHİN S., VURAL İ., ÖNER L.
2016 AAPS Annual Meeting and Exposition, 13 - 17 November 2016
- XVIII. **Evaluation of Surfactant Effect on the Saturation Solubility and Permeability of Deferasirox**
AKDAĞ ÇAYLI Y., GÜLSÜN İNAL T., İZAT N., ÖNER L., ŞAHİN S.
2016 AAPS Annual Meeting and Exposition, 13 - 17 November 2016
- XIX. **Levofloxacin Dry Powder for Inhalation by Spray Drying Method**
AKDAĞ ÇAYLI Y., ŞAHİN S., Buttini F., Balducci A. G., Montanari S., VURAL İ., ÖNER L.
2016 AAPS Annual Meeting and Exposition, 13 - 17 November 2016
- XX. **Effect of Particle Size on Deferasirox Dissolution Time**
GÜLSÜN İNAL T., AKDAĞ ÇAYLI Y., İZAT N., ÖNER L., ŞAHİN S.
2016 AAPS Annual Meeting and Exposition, 13 - 17 November 2016
- XXI. **Determination of Permeability of Ciprofloxacin Dry Powder Inhaler Formulations Across Calu 3 Cell Line**
AKDAĞ ÇAYLI Y., ŞAHİN S., VURAL İ., ÖNER L.
2016 AAPS Annual Meeting and Exposition, 13 - 17 November 2016
- XXII. **Formulation and Characterization of Mometasone Furoate Monohydrate and Formoterol Fumarate**

- Dihydrate Containing Dry Powder Inhaler Formulations**
AKDAĞ ÇAYLI Y., GÜLSÜN İNAL T., İZAT N., ÖNER L., ŞAHİN S.
2016 AAPS Annual Meeting and Exposition, 13 - 17 November 2016
- XXIII. Development and Evaluation of Terbutaline Sulfate Containing Orally Disintegrating Tablets**
İZAT N., AKDAĞ ÇAYLI Y., GÜLSÜN İNAL T., KAYNAK M. S., ÖNER L., ŞAHİN S.
2016 AAPS Annual Meeting and Exposition, 13 - 17 November 2016
- XXIV. Determination and Evaluation of Aerodynamic Parameters of Ciprofloxacin and Mucolytic Containing Dry Powder Inhalers**
AKDAĞ ÇAYLI Y., ŞAHİN S., BUTTINI F., BALDUCCI A. G., MONTANARI S., VURAL İ., ÖNER L.
The Globalization of Pharmaceutics Education Network (GPEN) 2016, 9 - 12 November 2016
- XXV. Development and Validation of an HPLC Method for Determination of Rofecoxib**
DEMİRTÜRK E., İZAT N., AKDAĞ ÇAYLI Y., GÜLSÜN İNAL T., ŞAHİN S., ÖNER L.
18th International Pharmaceutical Technology Symposium, 18 - 21 September 2016
- XXVI. Preparation and Evaluation of Lyophilized Orally Disintegrating Tablets Containing Terbutaline Sulphate**
İZAT N., AKDAĞ ÇAYLI Y., GÜLSÜN İNAL T., DEMİRTÜRK E., ÇETİN M., ÖNER L., ŞAHİN S.
18th International Pharmaceutical Technology Symposium, 18 - 21 September 2016
- XXVII. EVALUATION OF PERMEABILITY OF LEVOFLOXACIN CONTAINING DRY POWDER INHALER ACROSS CALU 3 CELL LINE**
AKDAĞ ÇAYLI Y., ŞAHİN S., VURAL İ., ÖNER L.
18th International Pharmaceutical Technology Symposium, 18 - 21 September 2016
- XXVIII. Development and In vitro Evaluation of Deferasirox Orally Disintegrating Tablets by Lyophilization Method**
GÜLSÜN İNAL T., İZAT N., AKDAĞ ÇAYLI Y., DEMİRTÜRK E., ÇETİN M., ÖNER L., ŞAHİN S.
18th International Pharmaceutical Technology Symposium, 18 - 21 September 2016
- XXIX. Influence of Verapamil On Metformin Permeability Across Caco 2 Cells**
GÜLSÜN İNAL T., İZAT N., AKDAĞ ÇAYLI Y., ÖNER L., ŞAHİN S.
1st International Gazi Pharma Symposium Series, 12 - 15 November 2015
- XXX. Development of Metformin Hydrochloride and Glyburide Containing Orally Disintegrating Tablets**
GÜLSÜN İNAL T., İZAT N., AKDAĞ ÇAYLI Y., KAYNAK M. S., ÖNER L., ŞAHİN S.
2015 AAPS Annual Meeting and Exposition, 25 - 29 October 2015
- XXXI. Preparation and Evaluation of Deferasirox Containing Orally Disintegrating Tablets by Direct Compression Method**
AKDAĞ ÇAYLI Y., GÜLSÜN İNAL T., İZAT N., ŞAHİN S., ÖNER L.
2015 AAPS Annual Meeting and Exposition, 25 - 29 October 2015
- XXXII. Formulation and Characterization of Ciprofloxacin and Mucolytic Containing Dry Powder Inhaler Formulations**
AKDAĞ ÇAYLI Y., ŞAHİN S., VURAL İ., ÖNER L.
2015 AAPS Annual Meeting and Exposition, 25 - 29 October 2015
- XXXIII. Evaluation of Dissolution Results of Commercially Available Metformin Hydrochloride Tablets**
İZAT N., AKDAĞ ÇAYLI Y., GÜLSÜN İNAL T., ÖNER L., ŞAHİN S.
2015 AAPS Annual Meeting and Exposition, 25 - 29 October 2015
- XXXIV. Formulation and Characterization of Levofloxacin and Mucolytic Containing Dry Powder Inhaler Formulations**
AKDAĞ ÇAYLI Y., ŞAHİN S., VURAL İ., ÖNER L.
3rd International TB-Meeting, 14 - 16 October 2015
- XXXV. Investigation of permeabilities of metformin and glyburide from orally disintegrating tablets**
ŞAHİN S., GÜLSÜN İNAL T., İZAT N., AKDAĞ ÇAYLI Y., ÖNER L.
6th BBBB Conference on Pharmaceutical Sciences, 10 - 12 September 2015
- XXXVI. Permeability studies of orally disintegrating tablets containing deferasirox**
ŞAHİN S., AKDAĞ ÇAYLI Y., GÜLSÜN İNAL T., İZAT N., ÖNER L.

6th BBBB Conference on Pharmaceutical Sciences, 10 - 12 September 2015

- XXXVII. **Investigation of metformin permeability from commercially available metformin hydrochloride tablets**

ŞAHİN S., İZAT N., AKDAĞ ÇAYLI Y., GÜLSÜN İNAL T., ÖNER L.

6th BBBB Conference on Pharmaceutical Sciences, 10 - 12 September 2015

- XXXVIII. **Formulation and Characterization of Antibiotic and Mucolytic Containing Dry Powder Inhaler Formulations**

AKDAĞ ÇAYLI Y., ŞAHİN S., VURAL İ., ÖNER L.

1st European Conference on Pharmaceutics : Drug Delivery, 13 - 14 April 2015

- XXXIX. **Formulation and Characterization of Ciprofloxacin Nanoparticles for Use in Dry Powder Inhalers**

AKDAĞ ÇAYLI Y., ŞAHİN S., VURAL İ., ÖNER L.

17th International Pharmaceutical Technology Symposium, 8 - 10 September 2014

Supported Projects

PEHLİVAN S., ÇAKIR AKTAŞ C., AYTEKİN E., YAZICI G., ÖNER L., ÖZTÜRK S. C., AKDAĞ ÇAYLI Y., ÇELİK AKDUR E., MUT AŞKUN M., Project Supported by Higher Education Institutions, Glioblastom Tedavisinde İleri Yaklaşım Tümör Mikroçevresine Duyarlı ve Dual Etkili Nanopartiküler Sistemlerin Radyoterapinin Etkinliğini Artırmak İçin Tasarlanması ve Değerlendirilmesi (220S765 No'lu TÜBİTAK 1001 Projesine Ek Bütçe Desteği), 2022 - Continues
GÜLSÜN İNAL T., AKDAĞ ÇAYLI Y., ŞAHİN S., SİLİNİNDİR GÜNEY M., DEMİR KABAŞ H., Öztürk B. D., Project Supported by Higher Education Institutions, Fotodinamik tedavi yaklaşımı kullanılarak Alzheimer hastalığının tedavisinde etkinliği artırmak amacıyla metilen mavisi ve galantamin yüklü polimerik nanopartiküllerin geliştirilmesi ve in vitro karakterizasyonları, 2022 - Continues
AKDAĞ ÇAYLI Y., GÜLSÜN İNAL T., NEMUTLU E., ÖNER L., ŞAHİN S., ÖZTÜRK S. C., Geyik Z. M., Bebek G., Project Supported by Higher Education Institutions, Küçük hücreli dışı akciğer kanseri tedavisinde endüstriye uygulanabilir yüksek teknoloji ürünü nanoteknolojik tümöre hedeflendirilmiş kuru toz inhaler formülasyonu geliştirilmesi invitro ve invivo değerlendirmesi (120S895 numaralı projeye ek bütçe desteği), 2022 - 2024
Gülsün İnal T., Sahin S., Akdağ Çaylı Y., Öner L., İnal M., Kazkayası Bölük İ., Güler M. T., TUBITAK Project, Alzheimer Hastalığında Tedavi Etkinliğini Artırmak Amacıyla; Yüzey Modifikasyonu İle Kan Beyin Bariyerinden Geçişi Artırılmış Nanopartiküller İçeren Mikroigne Formülasyonlarının Geliştirilmesi, In Vitro, Ex-Vivo Ve In Vivo Çalışmalar, 2021 - 2024
Akdağ Çaylı Y., Öner L., Arslan A., Yet B., Eroğlu H., TUBITAK Project, Seleoksib İçeren Formülasyonların Çözünürlük Ve Çözünme Özelliklerinin Yapay Sinir Ağrı Tasarımı Kullanılarak Optimizasyonu, 2020 - 2021
ÖNER L., AKDAĞ ÇAYLI Y., Project Supported by Higher Education Institutions, ANTİBİYOTİK İÇEREN KURU TOZ İNHALER FORMÜLASYONU TASARIMI VE PERMEABİLİTE ÇALIŞMALARI, 2017 - 2017
TUBITAK Project, Antibiyotik ve Mukolitik İçeren İnhaler Formülasyonu Tasarımı Karakterizasyonu ve Permeabiliteye Etkilerinin Değerlendirilmesi, 2014 - 2015

Metrics

Publication: 63

Citation (WoS): 71

Citation (Scopus): 136

H-Index (WoS): 5

H-Index (Scopus): 7

Non Academic Experience

SAĞLIK BAKANLIĞI

